SEC Form SC 13G filed by CareMax Inc.

SEC Form SC 13G filed by CareMax Inc.

Recent Analyst Ratings for
$CMAX

$CMAX
Press Releases

$CMAX
Analyst Ratings

$CMAX
Leadership Updates

$CMAX
SEC Filings

$CMAX
Insider Trading

$CMAX
Large Ownership Changes

Chat with this insight

Fastest customizable press release news feed in the world

CareMax Enters Into Agreement to Sell Core Centers' Assets

CareMax Reaches Agreements to Sell Management Services Organization and Core Centers' Assets

CareMax Reports Second Quarter 2024 Results

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

CareMax downgraded by Jefferies with a new price target

CareMax downgraded by UBS with a new price target

CareMax downgraded by Piper Sandler with a new price target

Live Leadership Updates

Steward Health Care Appoints Rubén José King-Shaw Jr to Its Board of Directors

CareMax, Inc. Announces Board Leadership Transition

CareMax, Inc. Appoints Beatriz Assapimonwait to Board of Directors

CareMax Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

CareMax Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update, Financial Statements and Exhibits

SEC Form NT 10-Q filed by CareMax Inc.

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3 filed by new insider Borkowski Edward

SEC Form 3 filed by new insider Rundell Paul Brent

Flynn James E converted options into 12,123 shares (SEC Form 4)

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by CareMax Inc. (Amendment)

2/11/22 4:34:29 PM ET

$CMAX

Hospital/Nursing Management

Health Care

Get the next $CMAX alert in real time by email

SC 13G 1 d315928dsc13g.htm SC 13G SC 13G

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

§ 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2

Under the Securities Exchange Act of 1934

(Amendment No. )*

CareMax, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.0001 per share

(Title of Class of Securities)

14171W103

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP NO. 14171W103		13G		Page 2 of 12 Pages


CUSIP NO. 14171W103		13G		Page 3 of 12 Pages


CUSIP NO. 14171W103		13G		Page 4 of 12 Pages


CUSIP NO. 14171W103		13G		Page 5 of 12 Pages


CUSIP NO. 14171W103		13G		Page 6 of 12 Pages


CUSIP NO. 14171W103		13G		Page 7 of 12 Pages


CUSIP NO. 14171W103		13G		Page 8 of 12 Pages

Item 1(a).

Name of Issuer:

CareMax, Inc. (the “Issuer”)

Item 1(b).

Address of Issuer’s Principal Executive Offices:

100 NW 57 Court, Suite 400

Miami, Florida 33126

Item 2(a).

Name of Person Filing:

This statement (this “Statement”) is filed by the following persons (the “Reporting Persons”):

Athyrium Opportunities III Acquisition LP (“Acquisition”)

Athyrium Opportunities III Acquisition 2 LP (“Acquisition 2” and, together with Acquisition, the “Acquisition Funds”)

Athyrium Opportunities Associates III LP (“Associates III LP”)

Athyrium Opportunities Associates III GP LLC (“Associates III GP”)

Athyrium Funds GP Holdings LLC (“Funds GP Holdings”)

Jeffrey A. Ferrell (“Mr. Ferrell”)

The Reporting Persons’ beneficial ownership of the Issuer’s shares of Common Stock reported herein consist of Class A Common Stock, par value $0.0001 per share, held directly by the Acquisition Funds.

Pursuant to Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the Reporting Persons have entered into an agreement with respect to the joint filing of this Statement, which agreement is set forth on the signature page to this Statement.

Item 2(b).

Address of Principal Business Office or, if none, Residence:

The principal business office address for each of the Reporting Persons is:

c/o Athyrium Capital Management, LP

505 Fifth Avenue, Floor 18

New York, New York 10017

Item 2(c).

Citizenship:

The Acquisition Funds and Associates III LP are Delaware limited partnerships.

Associates III GP and Funds GP Holdings are Delaware limited liability companies.

Mr. Ferrell is a United States citizen.

Item 2(d).

Title of Class of Securities:

Class A Common Stock, par value $0.0001 per share, of the Issuer (“Common Stock”)

Item 2(e).

CUSIP Number:

14171W103


CUSIP NO. 14171W103		13G		Page 9 of 12 Pages

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable. Filed pursuant to Rule 13d-1(d).

Item 4.

Ownership.

(a)

Amount beneficially owned: 4,487,219 shares of Common Stock

See the responses to Item 9 on the attached cover pages

(b)

Percent of class:

See the responses to Item 11 on the attached cover pages.

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote:

See the responses to Item 5 on the attached cover pages.

(ii)

Shared power to vote or to direct the vote:

See the responses to Item 6 on the attached cover pages.

(iii)

Sole power to dispose or to direct the disposition of:

See the responses to Item 7 on the attached cover pages.

(iv)

Shared power to dispose or to direct the disposition of:

See the responses to Item 8 on the attached cover pages.

The filing of this Statement shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

Item 6.

Ownership of More Than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.


CUSIP NO. 14171W103		13G		Page 10 of 12 Pages

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certifications.

Not applicable.


CUSIP NO. 14171W103		13G		Page 11 of 12 Pages

SIGNATURES

After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this Statement is true, complete and correct.

In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of this Statement on Schedule 13G with respect to the shares of Common Stock of the Issuer.


Dated: February 11, 2022

ATHYRIUM OPPORTUNITIES III ACQUISITION LP

By:	ATHYRIUM OPPORTUNITIES ASSOCIATES III LP, its General Partner

	By:	ATHYRIUM OPPORTUNITIES
		ASSOCIATES III GP LLC, its General Partner

	By:	/s/ Andrew Hyman
	Name:	Andrew Hyman
	Title:	Senior Vice President, Secretary

ATHYRIUM OPPORTUNITIES III ACQUISITION 2 LP

By:	ATHYRIUM OPPORTUNITIES ASSOCIATES III LP, its General Partner

	By:	ATHYRIUM OPPORTUNITIES
		ASSOCIATES III GP LLC, its General Partner

	By:	/s/ Andrew Hyman
	Name:	Andrew Hyman
	Title:	Senior Vice President, Secretary

ATHYRIUM OPPORTUNITIES ASSOCIATES III LP

By:	ATHYRIUM OPPORTUNITIES ASSOCIATES III GP LLC, its General Partner

	By:	/s/ Andrew Hyman
	Name:	Andrew Hyman
	Title:	Senior Vice President, Secretary


CUSIP NO. 14171W103		13G		Page 12 of 12 Pages


ATHYRIUM OPPORTUNITIES ASSOCIATES III GP LLC

By:		/s/ Andrew Hyman
Name:		Andrew Hyman
Title:		Senior Vice President, Secretary

ATHYRIUM FUNDS GP HOLDINGS LLC

By:		/s/ Jeffrey A. Ferrell
Name:		Jeffrey A. Ferrell
Title:		Managing Member

By:		/s/ Jeffrey A. Ferrell
Name:		JEFFREY A. FERRELL

Get the next $CMAX alert in real time by email

Date	Price Target	Rating	Analyst
2/26/2024	$1.50 → $7.50	Buy → Hold	Jefferies
11/17/2023	$5.00 → $1.00	Buy → Neutral	UBS
11/10/2023	$3.00 → $2.00	Overweight → Neutral	Piper Sandler
3/17/2023	$7.00 → $4.00	Outperform → Market Perform	TD Cowen
9/7/2022	$7.50	Hold	Truist
1/7/2022	$14.00	Buy	UBS
10/20/2021	$15.00	Buy	Jefferies
9/13/2021	$14.00	Neutral → Overweight	Piper Sandler

NAMES OF REPORTING PERSONS

ATHYRIUM OPPORTUNITIES III ACQUISITION 2 LP

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐ (b) ☐

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

STATE OF DELAWARE, UNITED STATES OF AMERICA